ARTICLE | Product Development
Combo confidence
Vertex, trial investigators look past data hiccup in cystic fibrosis study
June 4, 2012 7:00 AM UTC
Vertex Pharmaceuticals Inc. and two academic investigators contend that a missed primary endpoint, a data snafu and atypical results in placebo patients all should take a back seat to FEV1 improvements produced by the company's VX-809 plus Kalydeco ivacaftor in a Phase II cystic fibrosis trial.
A clearer picture of the study should emerge shortly, as final data from all patients are expected by mid-year...